Table 2.
Clinical characteristics and risk factor associated with AF patients.
| Hazard ratio | 95% confidence interval | p-value | |
|---|---|---|---|
| AF recurrence per 1 AU increase in miR-21 (artery) | 1.104 | 0.398–3.063 | 0.850 |
| AF recurrence per 1 AU increase in miR-21 (vein) | 0.191 | 0.083–0.440 | <0.01* |
| AF recurrence per 1% increase in LVAs | 1.021 | 1.013–1.029 | <0.01* |
| Male sex | 0.94 | 0.573–1.543 | 0.807 |
| Age (per year) | 1.005 | 0.979–1.031 | 0.718 |
| BMI (per unit) | 1.016 | 0.970–1.064 | 0.502 |
| Previous PCI/CABG | 1.118 | 0.610–2.050 | 0.717 |
| Previous myocardial infarction | 1.052 | 0.455–2.434 | 0.905 |
| LV hypertrophy | 1.106 | 0.655–1.866 | 0.707 |
| Chronic kidney disease | 1.607 | 0.970–2.663 | 0.066 |
| Hypertension | 1.474 | 0.878–2.475 | 0.142 |
| CHA2DS2-VASc score (per point) | 1.032 | 0.877–1.216 | 0.702 |
| LVEF, % | 0.969 | 0.941–0.997 | 0.028* |
| LA size, mm | 1.075 | 1.021–1.133 | <0.01* |
| OSAS | 0.817 | 0.328–2.034 | 0.664 |
| Mitral valve disease | 1.997 | 0.985–4.051 | 0.055 |
| Diabetes mellitus | 0.973 | 0.510–1.858 | 0.934 |
b
AF, Atrial fibrillation; AU, Arbitrary unit; miR-21, microRNA-21; LVA, Low-voltage area; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; LV, Left ventricle; EHRA, European heart rhythm association; LVEF, Left ventricular ejection fraction; LA, Left atrium; OSAS, Obstructive sleep apnoea syndrome. *p < 0.05.